Draft:Iteos therapeutics

Submission declined on 20 December 2024 by KylieTastic (talk).

This draft's references do not show that the subject qualifies for a Wikipedia article. In summary, the draft needs multiple published sources that are:

in-depth (not just brief mentions about the subject or routine announcements)
reliable
secondary
strictly independent of the subject

Make sure you add references that meet all four of these criteria before resubmitting. Learn about mistakes to avoid when addressing this issue. If no additional references exist, the subject is not suitable for Wikipedia.

If you would like to continue working on the submission, click on the "Edit" tab at the top of the window.
If you have not resolved the issues listed above, your draft will be declined again and potentially deleted.
If you need extra help, please ask us a question at the AfC Help Desk or get live help from experienced editors.
Please do not remove reviewer comments or this notice until the submission is accepted.

Where to get help

If you need help editing or submitting your draft, please ask us a question at the AfC Help Desk or get live help from experienced editors. These venues are only for help with editing and the submission process, not to get reviews.
If you need feedback on your draft, or if the review is taking a lot of time, you can try asking for help on the talk page of a relevant WikiProject. Some WikiProjects are more active than others so a speedy reply is not guaranteed.

How to improve a draft

Wikipedia:Contributing to Wikipedia – a basic overview on how to edit Wikipedia.
Help:Wikitext – how to use the markup
Help:Referencing for beginners – how to include references
Wikipedia:Article development – how to develop your article
Wikipedia:Writing better articles – how to improve your article
Wikipedia:Verifiability – make sure your article includes reliable third-party sources

You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article.

Improving your odds of a speedy review

To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags.

Add tags to your draft

Editor resources

Easy tools: Citation bot (help) | Advanced: Fix bare URLs

Declined by KylieTastic 20 days ago. Last edited by KylieTastic 20 days ago. Reviewer: Inform author.

Resubmit

Please note that if the issues are not fixed, the draft will be declined again.

iTeos Therapeutics

Overview

iTeos Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of immuno-oncology therapeutics. The company is headquartered in Watertown, Massachusetts, United States, with additional operations in Gosselies, Belgium. Founded in 2012 as a spin-off from the Ludwig Institute for Cancer Research and de Duve Institute at the Université catholique de Louvain, iTeos aims to leverage insights into tumor biology and immunology to advance cancer treatments.^[1].

History

iTeos was established by Michel Detheux and Benoit Van den Eynde, both of whom are researchers specializing in immuno-oncology. Initially, the company focused on preclinical research and drug discovery, and it later transitioned to clinical development following the identification of key therapeutic candidates.

In July 2020, iTeos completed its initial public offering (IPO) and began trading on the NASDAQ stock exchange under the ticker symbol "ITOS." The IPO raised approximately $201 million to support the development of its clinical programs and expand its pipeline ^[2].

Collaborations

In June 2021, iTeos announced a collaboration with GlaxoSmithKline (GSK) to co-develop and commercialize EOS-448 (an anti-TIGIT drug). The partnership involved an upfront payment of $625 million to iTeos, with additional milestone payments and royalties. This collaboration is intended to accelerate the clinical development of EOS-448 by leveraging GSK’s global resources and expertise ^[3]

References

[1] ttps://www.iteostherapeutics.com

[2] ttps://www.goodwinlaw.com/en/news-and-events/news/2020/08/08_04-iteos-therapeutics-upsized-ipo

[3] ttps://www.gsk.com/en-gb/media/press-releases/gsk-and-iteos-therapeutics-announce-development/

[1]

[2]

[3]